FHTXFoghorn Therapeutics Inc.

$322M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$279,000

Gross Profit

-$18M-6581.7% margin

Operating Income

-$23M-8337.3% margin

Net Income

-$23M-8283.5% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$209M

Total Liabilities

$104M

Stockholders' Equity

$104M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$279,000	$0	—
Gross Profit	-$18M	$0	—
Operating Income	-$23M	-$16M	-49.7%
Net Income	-$23M	-$16M	-47.0%

FHTX Q2 2021 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena